Thirty-three per cent of the world’s population suffers from a neurological disease and 14% from mental illness. Research in these fields is essential.
There is a growing global concern about the increasing prevalence of mental health issues, which represents a great challenge for health systems. At Cinfa, our main objective is to offer a wide range of products in this therapeutic area.
According to the WHO, in 2019, 1 in 8 people, or 970 million people worldwide, were living with a mental disorder, with anxiety and depression disorders being the most common. In 2020, the number of people living with anxiety and depressive disorders increased significantly due to the Covid-19 pandemic. In addition, there is a high prevalence of mental disorders that affect children and young people. Many of these patients experience disease-related disabilities, decreased life expectancy, stigma, and discrimination.
A mental health policy and plan is essential to coordinate all mental health-related services and activities. Any action aimed at removing the stigma around mental health and encouraging people who are suffering in silence to seek help should also be welcomed.
For many mental health disorders, most studies suggest that a therapeutic approach consisting of a combination of medication and psychotherapy is more effective than either treatment method used alone. But of course, this is a decision that the doctor must make based on each patient’s situation.
“At Cinfa we focus on the treatment of peripheral and central neuropathic pain and epilepsy, and we contribute to innovation in this therapeutic area.”
– Dr Alicia Lez de Ocáriz, Corporate Medical Director at Cinfa Group.
The complexity of the brain and neurological illness
At the beginning of 2023, the World Health Organization (WHO) indicated that more than 33% of the world’s population already suffers from a neurological disease. Therefore, research in this field is essential, although it must be recognized that research on the brain has been and continues to be a great challenge due to its extreme complexity.
At Cinfa, we focus on the treatment of peripheral and central neuropathic pain and epilepsy within the therapeutic area dedicated to the Central Nervous System.
In addition, we are committed to innovation and have an R&D team with more than 100 people dedicated to the development of advanced healthcare solutions.
Global reach with a regional focus
Nearly 18 million people in the Middle East suffer from neurological diseases, causing more than 441,000 deaths a year. It is therefore important that collaboration with researchers and medical centres takes place for early detection of these diseases. At Cinfa, we collaborate with more than 8,500 medical centres and pharmacies in Saudi Arabia, Qatar, the United Arab Emirates and Kuwait to continue working in this and other areas.
- To learn more about Cinfa, visit: https://www.cinfainternational.com/cinfa/cinfa-worldwide/
